Advertisement
Protease Inhibitors (PIs)
When HIV infects a CD4 cell in a person's body, it copies its own genetic code into the cell's DNA. The CD4 cell is then "programmed" to make new HIV genetic material and HIV proteins. The proteins must be cut up by the HIV protease—a protein-cutting enzyme—to make functional new HIV particles. PIs block the protease enzyme and prevent the cell from producing new viruses. It is recommended that they be used in combination with at least two other HIV drugs to treat HIV infection.
*generic or biosimilar available
E experimental
| DRUG Aptivus |
|---|
|
| GENERIC NAME tipranavir |
| COMPANY Boehringer Ingelheim |
| DRUG Crixivan |
|---|
|
| GENERIC NAME indinavir |
| COMPANY Merck & Company |
| DRUG Evotaz |
|---|
|
| GENERIC NAME atazanavir + cobicistat |
| COMPANY Bristol-Myers Squibb |
| DRUG Invirase |
|---|
|
| GENERIC NAME saquinavir |
| COMPANY Genentech, a division of Roche |
| DRUG Kaletra |
|---|
|
| GENERIC NAME lopinavir + ritonavir |
| COMPANY AbbVie |
| DRUG Lexiva |
|---|
|
| GENERIC NAME fosamprenavir |
| COMPANY ViiV Healthcare |
| DRUG Norvir |
|---|
|
| GENERIC NAME ritonavir |
| COMPANY AbbVie |
| DRUG Prezcobix |
|---|
|
| GENERIC NAME darunavir + cobicistat |
| COMPANY Janssen Therapeutics |
| DRUG Prezista |
|---|
|
| GENERIC NAME darunavir |
| COMPANY Janssen Therapeutics |
| DRUG Reyataz* |
|---|
|
| GENERIC NAME atazanavir |
| COMPANY Bristol-Myers Squibb |
| DRUG Viracept |
|---|
|
| GENERIC NAME nelfinavir |
| COMPANY ViiV Healthcare |
Advertisement
